Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 720 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03577327Recruiting
Study gut and skin germs in vitiligo progression
This study looks at differences in the gut and skin microbiome (the germs living in and on the body) in people with vitiligo and in people without vitiligo. It aims to understand what might be linked to how vitiligo spreads over time.
Chicago, IllinoisAges 18–89 - NCT03594760RecruitingPhase 3
PSMA PET scan study using advanced computer imaging in prostate cancer
This Phase 3 study looks at how a PSMA PET scan can predict how prostate cancer will progress and how well treatment is working. If your doctor at CHUM orders this scan, you may be able to join to help refine better predictions for future patients.
Montreal, QuebecAges 18 years+ - NCT03631953RecruitingPhase 1
Test alpelisib plus trametinib for hard-to-treat meningiomas
This Phase 1 trial studies whether combining two targeted medicines—alpelisib and trametinib—can shrink or slow progressive meningiomas that have already been treated with standard surgery and radiation. If you qualify, you may help test a new treatment approach for tumors that keep growing.
MarseilleAges 18 years+ - NCT03663790Recruiting
Gait retraining for knee osteoarthritis movement patterns
This trial tests whether a structured walking retraining program can improve how your leg moves if you have knee osteoarthritis. It may help reduce strain on your lower body during walking by changing walking technique.
Manassas, VirginiaAges 18–80 - NCT03769766RecruitingPhase 3
Curcumin to help keep low-risk prostate cancer from worsening
This study tests whether curcumin (a supplement made from turmeric) can prevent low-risk prostate cancer from progressing while you stay on active surveillance. If you qualify, you would take curcumin and be monitored closely with regular checkups.
Dallas, TexasAges 40–89 - NCT03789253Recruiting
Tracking genetic changes as low-risk prostate cancer becomes riskier
This study looks for genes and biological pathways that may explain why some men’s prostate cancer grows from low risk to higher risk. You may be followed using planned prostate biopsies after an initial low-risk diagnosis managed with active surveillance.
TaipeiAges 40–100 - NCT03853447Recruiting
Study of inflammation changes from pancreas flare to chronic disease
This trial studies how “inflammation” in the pancreas changes over time—going from a first or repeated attack to long-term (chronic) pancreatitis. It may help doctors understand what drives progression and identify people at higher risk for chronic disease.
Hvidovre, Capital Region DenmarkAges 18–70 - NCT03872102Recruiting
Brain imaging study to track Parkinson-related disease changes
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
Dallas, TexasAges Any age - NCT03981276Recruiting
Study aims to understand inherited walking stiffness disorders
This study looks at the causes and biology (“biomarkers”) of hereditary spastic paraplegias and related conditions. You may join as someone with the condition, a family member without symptoms, or a healthy person, to help researchers understand what’s happening in the nervous system.
InnsbruckAges Any age - NCT04000061Recruiting
Tracking heart failure and heart attack progress in hospital
This study looks at how heart problems progress while you’re in the hospital, using your medical information (clinical data). It may help doctors better predict outcomes and improve care for people with heart attacks and heart failure.
BaselAges 18 years+ - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT06022146RecruitingPhase 3
Short TB prevention for school contacts
This trial tests a very short (one-month) medicine course to prevent tuberculosis (TB) in students and school staff who have been exposed to someone with active TB. If you have latent TB infection (the germs are in your body but you're not sick), this treatment aims to stop it from turning into active TB disease.
Anshun, GuiyangAges 13 years+ - NCT07572383RecruitingPhase 2
Imaging Study of Immunosuppression for Progressive Lung Fibrosis
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
Boston, MassachusettsAges 18–80 - NCT04026360Recruiting
Study early lung, virus, and gut changes in children with cystic fibrosis
This study looks at how a child’s early lung function, viral infections, and gut (microbiome) changes affect cystic fibrosis over time. It may help doctors understand what predicts how lung disease develops, which could improve future care.
BernAges birth–18 years - NCT04082520RecruitingPhase 2
Lutathera for non-surgery meningioma that keeps growing
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
Rochester, MinnesotaAges 18 years+ - NCT04300062Recruiting
Rebiopsy of lung cancer after treatment no longer works
This trial studies patients with lung cancer whose disease has continued to grow despite immunotherapy. It involves taking a new tissue sample (a rebiopsy) to help doctors understand what changed during treatment and guide next steps.
Boulogne-BillancourtAges 18 years+ - NCT04473794Recruiting
Testing ways to assess pancreatic cyst risk and progression
This study looks at patients who have been referred for evaluation of a pancreatic cyst. It aims to improve how doctors estimate risk and predict how cysts may change over time.
Baltimore, MarylandAges 18 years+ - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Los Angeles, CaliforniaAges 18 years+ - NCT04520048Recruiting
Blood vessel tests to predict preeclampsia worsening in pregnancy
This study measures blood vessel–related markers in pregnant people who already have high blood pressure or early preeclampsia. The goal is to predict who is more likely to get worse, so care can be better targeted.
Bobigny, Seine Saint DenisAges 18–40 - NCT04525833Recruiting
Visit Tzu Chi gastroenterology clinic study
This study looks at people who have visited a Tzu Chi Hospital gastroenterology clinic. It may help researchers understand liver and other whole-body health conditions in patients who receive care there.
New Taipei CityAges 18–99 - NCT04541654Recruiting
Study of families with TP53 gene changes in Li-Fraumeni syndrome
This study is looking at how people in families with certain TP53 gene changes (including Li-Fraumeni syndrome) develop health problems over time. It may help doctors better understand risk and improve care for affected families.
Boston, MassachusettsAges Any age - NCT04591002RecruitingPhase 2
Osimertinib after lung cancer surgery to slow new lung spots
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
Seoul, KangnamguAges 30–75 - NCT04606732Recruiting
Tracking heart risk changes after COVID-19 hospitalization
This study looks at how COVID-19 affects heart health over time in people who were hospitalized. Your results may help doctors predict prognosis and understand who is at higher heart risk after recovery.
BolognaAges 18 years+ - NCT04692675Recruiting
MRI study to track prostate cancer in active surveillance patients
This study uses special prostate MRI scans to see how prostate cancer changes over time while you stay on active surveillance. It also looks at prostate tissue to understand your cancer’s genetics, which may help guide future decisions.
Bethesda, MarylandAges 18 years+
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 720 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.